|
gptkbp:instanceOf
|
gptkb:anticoagulant
factor Xa inhibitor
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:ATCCode
|
B01AF03
|
|
gptkbp:brand
|
gptkb:Lixiana
gptkb:Savaysa
|
|
gptkbp:CASNumber
|
480449-70-5
|
|
gptkbp:chemicalClass
|
pyridinecarboxamide
|
|
gptkbp:contraindication
|
active pathological bleeding
severe hepatic impairment
|
|
gptkbp:developer
|
gptkb:Daiichi_Sankyo
|
|
gptkbp:eliminationHalfLife
|
10-14 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C24H30ClN7O4S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Edoxaban
|
|
gptkbp:KEGGID
|
D09964
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits factor Xa
|
|
gptkbp:MedlinePlusID
|
a614048
|
|
gptkbp:metabolism
|
minimal hepatic
|
|
gptkbp:pregnancyCategory
|
gptkb:B3
N
not recommended
|
|
gptkbp:proteinBinding
|
55%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2108508
25143998
DB09075
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
bleeding
rash
|
|
gptkbp:UNII
|
A4X639N98C
|
|
gptkbp:usedFor
|
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
|
|
gptkbp:bfsParent
|
gptkb:Daiichi_Sankyo
|
|
gptkbp:bfsLayer
|
6
|